Accelerate Your Preclinical Research By InnoSer’s Innovative Methods.

Customizing in vitro and in vivo services for your success.

Recently At InnoSer

A day in the life of InnoSer’s Intern Marketing Analysts Meilin Berkhoff & Amber Schonk

by Casey | July 12, 2021 | Blog, Interview, Staff | 0 Comments

Meilin and Amber are both students of Leiden University completing their Masters in Biomedical Sciences Management. As part of their study requirements, Amber and Meilin are with us for a total of 6 months and will step into the role of marketing analysts. They...

TRANSCEND: developing a novel platform integrating organoid and humanized in vivo models for Parkinson’s Disease

by admin | June 29, 2021 | Blog, Grants, News, Services | 0 Comments

The TRANSCEND project aims to tackle the current limitations of drug development for Parkinson’s Disease by the integration of an innovative in vitro brain organoid model and a humanized in vivo mouse model. This unique two-step platform supports InnoSer’s aspiration...

On a mission to bring smart science to patients: a new chapter in InnoSer history

by admin | June 24, 2021 | Blog, Events, News | 0 Comments

As the InnoSer team, we are delighted to share the news – as of this week, we have a renewed vision and mission statement, as well as a renewed logo to accompany them. With these changes, we are ready more than ever not only for our continued growth and strong team...

THERAPEUTIC AREAS

We Specialize In

InnoSer’s INNOVATIVE METHODS

Combining In Vivo And In Vitro

By our state-of-the-art methods from organoids to genetically engineered mice, we provide reliability and transferability in your results.

Low success rates of drugs that are able to go from bench to the clinic continue to disappoint not only researchers and pharmaceutical companies but also patients and their families. The resulting expenses affect the costs of all drugs that reach the market.

This calls for more stringent criteria at the preclinical phase, ensuring only the drugs that are effective and safe for humans continue to the clinical phases. InnoSer excels in combining in vitro and in vivo disease modelling to offer the most reliable screening platforms.

By developing in-vitro technologies and knowledge that offer higher predictive capacity, we support the transition to a world that relies less on animal testing.

SERVICES OVERVIEW

GET IN TOUCH WITH US

Tell Us About Your Work

We always keep close contact with our customers to identify and understand their needs better. All our services can be customized for your project requirements.

START A CONVERSATION

OUR CLIENTS ABOUT US

Academic And Commercial Expertise

“We truly enjoyed working with the InnoSer team. They bring an outstanding scientific knowledge into the oncology field in combination with high flexibility. InnoSer provided us with and executed a preclinical study project tailored to our needs, and within the agreed timelines. We will definitely work with InnoSer for our future drug development needs.”

Ad van de Gorp PhD, CEO Cythura Therapeutics

“Starting a biotech company was something completely new for me. InnoSer supported me in developing the study protocol and with all additional hassle like ethical protocols, logistics, ordering study materials etc. We worked closely with the InnoSer staff and I truly appreciate their professionalism and dedication.”

Joost van Bree, CEO Saillant Therapeutics

SEE ALL TESTIMONIALS



Phone

+32 (0)11 14 07 68



Headquarters

InnoSer België NV

Agoralaan A bis
3590 Diepenbeek
Belgium



Email

info@innoserlaboratories.com



Subsidiary

InnoSer Nederland BV

Zernikedreef 9
2333 CK Leiden
The Netherlands